Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer
- PMID: 2065272
- DOI: 10.1002/1097-0142(19910801)68:3<532::aid-cncr2820680314>3.0.co;2-g
Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer
Abstract
Estrogen receptors (ER) and epidermal growth factor receptors (EGFR) in the tumor cells of breast cancer tissues (primary tumors) and metastatic lymph nodes (involved nodes) were analyzed by immunocytochemical study in 19 patients; 12 were ER positive, and seven were ER negative. Microscopic study was used to determine the percentage of positive cells and the staining index. The percentage of EGFR-positive cells and the EGFR staining index were higher in the ER-negative primary tumors than ER-positive primary tumors. In ER-positive cases, both the number of ER-positive cells and ER content per cell was less in the involved nodes than in the primary tumors, whereas the number of EGFR-positive cells and EGFR content per cell was greater in affected nodes. On the other hand, in the ER-negative cases the number of EGFR-positive cells and EGFR content per cell remain almost unchanged between the primary tumors and involved nodes. The authors supposed a probability, in this study, that estrogen may exert inhibitory action on EGFR production through binding to ER.
Similar articles
-
Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: relationship to estrogen receptor and lymphatic invasion.Int J Cancer. 1989 Feb 15;43(2):220-5. doi: 10.1002/ijc.2910430208. Int J Cancer. 1989. PMID: 2645219
-
Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer.Int J Cancer. 1995 Dec 11;63(6):790-3. doi: 10.1002/ijc.2910630607. Int J Cancer. 1995. PMID: 8847135
-
Prognostic value of epidermal growth factor receptor in node-positive breast cancer.Breast Cancer Res Treat. 1989 Oct;14(1):77-90. doi: 10.1007/BF01805978. Breast Cancer Res Treat. 1989. PMID: 2690971 Clinical Trial.
-
Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.Int J Surg Pathol. 2005 Oct;13(4):319-27. doi: 10.1177/106689690501300403. Int J Surg Pathol. 2005. PMID: 16273187
-
Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer.Br J Cancer. 1994 Jun;69(6):1032-7. doi: 10.1038/bjc.1994.203. Br J Cancer. 1994. PMID: 8198966 Free PMC article.
Cited by
-
Juvenile gigantomastia: report of a case.Surg Today. 1993;23(3):260-4. doi: 10.1007/BF00309238. Surg Today. 1993. PMID: 8467179
-
The epidermal growth factor receptor in breast cancer.J Mammary Gland Biol Neoplasia. 1997 Apr;2(2):131-41. doi: 10.1023/a:1026399613946. J Mammary Gland Biol Neoplasia. 1997. PMID: 10882299 Review.
-
The in vitro and in vivo anti-tumor effect of KO-202125, a sauristolactam derivative, as a novel epidermal growth factor receptor inhibitor in human breast cancer.Cancer Sci. 2011 Mar;102(3):597-604. doi: 10.1111/j.1349-7006.2010.01817.x. Epub 2011 Jan 10. Cancer Sci. 2011. PMID: 21205071 Free PMC article.
-
High positive rate of pS2 expression in forefront intraductal cancerous area in breast cancer.Jpn J Cancer Res. 1995 Nov;86(11):1035-40. doi: 10.1111/j.1349-7006.1995.tb03017.x. Jpn J Cancer Res. 1995. PMID: 8567393 Free PMC article.
-
Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer.Int J Exp Pathol. 2010 Aug;91(4):324-34. doi: 10.1111/j.1365-2613.2010.00709.x. Epub 2010 Apr 20. Int J Exp Pathol. 2010. PMID: 20412339 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous